Nielsen E H, Lindholm J, Laurberg P
Department of Endocrinology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.
Clin Endocrinol (Oxf). 2007 Nov;67(5):693-7. doi: 10.1111/j.1365-2265.2007.02947.x. Epub 2007 Jul 18.
Increased mortality has been reported in patients with pituitary disease, with some studies showing higher standard mortality rates (SMR) in women than in men.
To assess overall SMR for men and women with benign pituitary disease without excessive ATCH or GH secretion and to investigate associations between SMR and time period of diagnosis.
From searches in PubMed, Embase and Web of Science databases, and reference lists of major reviews and original articles, we included original studies providing SMR values and 95% confidence intervals (CI) for men and women separately. Thirty articles were studied in detail. Six studies were eligible for the meta-analysis of sex-specific mortality, and seven for the analysis of association between SMR and diagnosis period.
Individual studies (total 5412 patients) reported total SMR values (men and women together) ranging from 1.21 to 3.80. SMR varied from 0.98 to 3.36 in men and from 2.11 to 4.54 in women. Weighted SMR values were significantly higher in women (2.80; CI 2.59-3.02) than in men (2.06; CI 1.94-2 20) (P < 0.0001). SMR was negatively correlated with first year of diagnosis in individual studies (partial correlation analysis controlling for sex, P = 0.017), and approached normal in recent studies in men but not in women.
In our meta-analysis of patients with pituitary disease without ACTH or GH excess, SMR was significantly higher in women than in men. SMR reached normal levels in men treated in recent decades, but remained elevated in women.
据报道,垂体疾病患者的死亡率有所上升,一些研究表明女性的标准死亡率(SMR)高于男性。
评估无促肾上腺皮质激素(ATCH)或生长激素(GH)过度分泌的良性垂体疾病男性和女性的总体SMR,并研究SMR与诊断时间段之间的关联。
通过检索PubMed、Embase和科学网数据库以及主要综述和原始文章的参考文献列表,我们纳入了分别提供男性和女性SMR值及95%置信区间(CI)的原始研究。对30篇文章进行了详细研究。6项研究符合性别特异性死亡率的荟萃分析条件,7项研究符合SMR与诊断期关联分析的条件。
个别研究(共5412例患者)报告的总SMR值(男性和女性合计)在1.21至3.80之间。男性的SMR在0.98至3.36之间,女性在2.11至4.54之间。女性的加权SMR值(2.80;CI 2.59 - 3.02)显著高于男性(2.06;CI 1.94 - 2.20)(P < 0.0001)。在个别研究中,SMR与诊断的第一年呈负相关(控制性别后的偏相关分析,P = 0.017);在近期研究中,男性的SMR接近正常水平,而女性则不然。
在我们对无促肾上腺皮质激素或生长激素过多的垂体疾病患者的荟萃分析中,女性的SMR显著高于男性。近几十年来接受治疗的男性SMR达到正常水平,但女性仍居高不下。